Medicine needs in the paediatric health settingPMAG has identified a priority list of medicines requiring access for paediatric use in Australia, with some alterations made at this meeting. The medicines currently under consideration by PMAG are at Attachment A.
Members noted that, as a result of PMAG’s efforts, the listing for atenolol on the Pharmaceutical Benefits Scheme will be effective on 1 December 2012 and the listing for etanercept injection has been amended on 1 August 2012.
Liaison with stakeholdersMembers noted that PMAG had liaised with a number of pharmaceutical companies and expert paediatric groups since the last meeting to further discuss a number of medicines on PMAG’s priority list, and to seek advice on specific issues in paediatric medicine.
Liaison with other agenciesMembers noted that liaison with the Editorial Executive Committee of the Australian Prescriber would continue in relation to an article on the work that is being done to improve the availability of medicines for paediatric use in Australia.
PMAG is also involved in current antibiotic resistance surveillance activity, which is being led by the Australian Commission on Safety and Quality in Healthcare.
National and International developmentsMembers noted the ongoing national and international developments to improve access to medicines suitable for paediatric use. In terms of national developments, members noted the progress on the national paediatric medicines dosing resource.
Meeting OutcomesOutcome statements are provided after each meeting, so that members can distribute them widely to their networks. For further information on the Advisory Group, please visit the Paediatric Medicines Advisory Group webpage:
or contact the Advisory Group Secretariat:
Phone: (02) 6289 8023
Medicines currently under PMAG consideration - as at 31 October 2012
Clinical need as agreed by the PMAG
|Clindamycin suspension||Community acquired MRSA (in skin and soft tissue infection) and osteomyelitis|
|Calciferol/cholecalciferol||Vitamin D deficiency|
|Clobazam tablets||Resistant epilepsy|
|Triamcinolone hexacetonide||Steroid joint injections for juvenile idiopathic arthritis|
|Mycophenolate sodium||Nephrotic syndrome|
|Diazepam mixture||Chronic spasticity|
|Adalimumab||Uveitis related to juvenile idiopathic arthritis, enthesitis and crohn disease|
|Anakinra||Systemic juvenile idiopathic arthritis|
|Leflunomide||Juvenile idiopathic arthritis|
|Abatacept||Polyarticular juvenile idiopathic arthritis|
|Glycopyrrolate oral solution||Drooling|
|Melatonin||Sleep disorders (particularly those with neurological impairment/cortical blindness)|
|Natalizumab||Refractory multiple sclerosis|
|Kindergen||Medicinal food for older children|
|6-Mercaptopurine and Thioguanine suspension||Acute leukaemia|
|Tacrolimus suspension||Organ transplant|